Originally posted by the Voice of America.
Voice of America content is produced by the Voice of America,
a United States federal government-sponsored entity, and is in
the public domain.


Good Gut Microbes May Help Immunotherapy Drugs Shrink Tumors

by Reuters

   LONDON --

   Cancer patients with high levels of good gut bacteria appear more
   likely to respond to immunotherapy, potentially opening up a new way to
   optimize the use of modern medicines that are highly effective but only
   work in some people.

   The finding, reported in two scientific papers on Thursday, suggests
   patients may in future be told to actively nurture their good bugs when
   taking so-called PD-1 drugs like Merck & Co's Keytruda or Bristol-Myers
   Squibb's Opdivo.

   The twin publications in the journal Science are the latest examples of
   the importance of the microbiome - the vast community of microbes
   living inside us - which has been linked to everything from digestive
   disorders to depression.

   "You can change your microbiome, it's really not that difficult, so we
   think these findings open up huge new opportunities," said Jennifer
   Wargo of the MD Anderson Cancer Center in Texas, one of the study
   authors.

   Options for manipulating the microbiome including changes in diet,
   avoiding antibiotics, taking probiotics or - less appetizingly -
   receiving a fecal transplant, either as a capsule or by enema.

   Good bacteria seem to help in cancer by priming immune cells and
   smoothing the path for PD-1 drugs that work by taking the brakes off
   the immune system.

   Such immunotherapy drugs are revolutionizing cancer care, but only
   around 20 to 30 percent of patients respond, prompting a race by
   scientists and drug companies to find better ways to identify those who
   will benefit.

   The latest microbiome work in humans builds on initial research in mice
   in 2015, which first found a connection between good bacteria and
   immunotherapy drug responses.

   Now a team at the Gustave Roussy Cancer Campus in France has studied
   more than 200 patients taking PD-1 drugs for lung, kidney and bladder
   cancer. They found those on antibiotics, due to routine problems like
   urinary or dental infections, had worse survival prospects.

   Wargo's group, meanwhile, looked at melanoma patients and discovered
   that responders to immunotherapy had more diverse gut bacteria.

   The Texas team now plan to run a clinical trial to test the benefits of
   combining immunotherapy with microbiome modulation in cancer patients.

   Some biotech companies are already exploring this interface between the
   microbiome and cancer treatment, including Vedanta Biosciences, an
   affiliate of PureTech Health, which is doing pre-clinical research in
   the field.